Monosodium glutamate is going through a period that could be described as... spicy. This ubiquitous food additive, identified under the code E621, has just found itself in the spotlight of metabolic research with a study published in mid-November 2025 in the’International Journal of Obesity. And this time, it's not the famous «Chinese restaurant syndrome» that's taking centre stage, but something much more profound: the ability of MSG to reprogramme the metabolism of future generations.
Hassan and colleagues have just demonstrated in rodents that maternal exposure to MSG during gestation permanently disrupts hormonal signalling in the hypothalamus of the male offspring, creating a favourable environment for obesity and metabolic dysfunctions from childhood onwards[1], a mechanism that involves the activation of well-known inflammatory pathways (NF-κB and mTOR).
DOHaD: when the foetus records the maternal menu
The paradigm of Developmental Origins of Health and Disease (DOHaD) is no longer a niche hypothesis. Since the pioneering work of David Barker in the 1990s, we have known that the prenatal nutritional environment conditions the risk of chronic diseases in adulthood. What Hassan's team has revealed is the precise mechanism by which a food additive - MSG - can interfere with this developmental programming.
The protocol in brief :
- Exposure of pregnant rats to MSG (dose varied according to experimental group)
- Analysis of male offspring: body weight, metabolic parameters, hypothalamic gene expression
- Focus on the signalling pathways of leptin (a hormone responsible for satiety) and insulin
The results leave no room for doubt:
- Increased leptin and insulin resistance in the hypothalamus
- Chronic activation of NF-κB and mTOR inflammatory pathways
- Hyperphagia (increased food intake) and accumulation of body fat
- Unfavourable metabolic phenotype maintained into adulthood[1].
What is striking is the sexual specificity of the effects: male offspring are significantly more affected, suggesting a complex interaction between prenatal exposure and the foetal hormonal environment.
The hypothalamus, the metabolic conductor under influence
To understand the scope of this discovery, we need to remind ourselves. The hypothalamus is the nerve centre of energy regulation. It is here that neurons sensitive to leptin (produced by adipose tissue) and insulin (produced by the pancreas) detect the state of energy reserves and adjust food intake accordingly.
When these circuits are functional, the body «knows» when it has had enough to eat. When they are damaged - by chronic inflammation, oxidative stress or developmental disturbance - the satiety signal no longer gets through. The result: overeating, weight gain and a vicious metabolic circle.
MSG acts as a neuroendocrine disrupter:
- It activates the NF-κB and mTOR pro-inflammatory pathways from gestation onwards
- These pathways alter the transmission of leptin/insulin signals
- Hypothalamic neurons become «deaf» to satiety hormones
- The offspring inherit a defective energy regulation system[1].
This is not acute intoxication. It is a silent and lasting reprogramming.
MSG and regulation: «GRAS» status put to the test by developmental biology
Monosodium glutamate has enjoyed an enviable regulatory status for decades: Generally Recognized As Safe (GRAS) in the United States, ADI (Acceptable Daily Intake) «not specified» according to EFSA and the WHO. Conventional toxicological assessments have never identified any major risk at current dietary doses[2].
But here's the rub: these assessments are based on models of acute and sub-acute toxicity in adults. They take little or no account of developmental windows of vulnerability. pregnancy, This is where the neuroendocrine systems are built and calibrated.
Hassan's study does not call into question the general use of MSG. It questions the adequacy of evaluation protocols in the face of emerging evidence on prenatal metabolic programming. And it poses a strategic question: Should an additive be maintained in sensitive segments (maternal and infant nutrition) in the name of a GRAS status established on other scientific bases?[3]
The ingredients sector faces an innovation dilemma
For ingredient suppliers and formulators, this type of publication is not just an academic signal. It is a marker of changes in customer expectations, CSR guidelines and differentiation strategies.
Three scenarios are emerging:
1. Proactive anticipation: substitution and clean label
Develop alternative umami solutions (yeast extracts, precise fermentations, bioactive peptides) that reproduce the taste intensity of MSG without exposure to a potential developmental risk. This strategy is already underway at several biotech and food-tech companies, driven by the growing demand for «mother-friendly» formulations.
2. Greater transparency: evidence-based communication
To document, via controlled clinical studies, the metabolic neutrality of formulations containing MSG in realistic scenarios of maternal exposure. This will require investment in translational research and close collaboration with academic teams.
3. Strategic segmentation: differentiation by use
Maintaining MSG in «mainstream» consumer applications (where the sensory benefit remains undeniable) while withdrawing it from ranges explicitly targeting pregnant and breast-feeding women and young children. A pragmatic approach that preserves market share while limiting exposure to criticism.
From science to strategy: operational implications
The emergence of data on the metabolic programming associated with food additives is not an isolated phenomenon. It is part of a wider movement to re-evaluate ingredients in the light of systems biology, the exposome and One Health.
Manufacturers must now integrate :
- A scientific watch extended to the fields of DOHaD, immunometabolism and neuroendocrinology
- Assessment protocols including developmental models (prenatal exposure, longitudinal follow-up)
- A transparent communication strategy distinguishing between absence of proof and proof of absence
The sector that anticipates these developments will gain credibility, legitimacy and the ability to influence future regulatory standards.
Things to remember
The study by Hassan et al. does not demonstrate that MSG is «toxic». It reveals a developmental mechanism of action that calls into question the relevance of its use in prenatal exposure situations. It is a signal, not a certainty. It is a call for vigilance, not a condemnation.
The facts:
- MSG disrupts leptin/insulin signalling in the hypothalamus of offspring (animal model)
- NF-κB and mTOR inflammatory pathways are chronically activated
- Male offspring have an increased metabolic risk (obesity, insulin resistance)[1].
Limitations:
- Studies carried out in rodents (transposition to humans to be confirmed)
- Exposure doses not always equivalent to real food scenarios
- Lack of randomised clinical trials in pregnant women
Opportunities :
- Innovation in umami clean label solutions
- Differentiation through proven developmental neutrality
- Opinion leadership on metabolic programming issues
MSG will not disappear from the global food landscape tomorrow. But its future in the premium, maternal and infant segments could well be decided over the next few years, depending on scientific data and the strategic choices made by manufacturers.
References
[1] Hassan, A.H., El Nashar, E.M., Al-Zahrani, N.S., et al. 2025. Maternal monosodium glutamate exposure disrupts leptin and insulin signaling in the hypothalamus, activating NF-κB and mTOR inflammatory pathways, contributing to metabolic dysfunction in male offspring. International Journal of Obesity. DOI: 10.1038/s41366-025-01941-z